J Fungi (Basel)
May 2024
There is an urgent need to develop new antifungals due to the increasing prevalence of multidrug-resistant fungal infections and the recent emergence of COVID-19-associated candidiasis. A good study model for evaluating new antifungal compounds is , an opportunistic fungal pathogen with intrinsic resistance to azoles (the most common clinical drugs for treating fungal infections). The aim of the current contribution was to conduct tests of antifungal metabolites produced by the bacteria Q, identify their molecular structures, and utilize several techniques to provide evidence of their therapeutic target.
View Article and Find Full Text PDF